The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Gadolinium Compounds Provide Insights into Pathogenesis of Fibrosing Diseases

Gadolinium Compounds Provide Insights into Pathogenesis of Fibrosing Diseases

November 9, 2012 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Toll-like receptors (TLRs) appear to play an important role in the pathogenesis of fibrotic disorders including nephrogenic systemic fibrosis (NSF) and systemic sclerosis. This discovery may open up a new area of investigation: the triggering of the fibrotic process by an environmental agent.

You Might Also Like
  • Research Links Macrophages with Pathogenesis of Inflammation, Fibrosis
  • Rheuminations: Rheumatologists Seek Better Understanding of Fibrosing Disorders
  • FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment
Also By This Author
  • Human RNAi Therapy Jumps Hurdle

One of the major causes of NSF is the exposure of patients with renal insufficiency to gadolinium-based contrast agents (GdBCAs) such as Omniscan. GdBCAs are used to enhance magnetic resonance imaging. GdBCAs contain a single Gd3+ ion that has increased solubility and decreased toxicity due to its being complexed to either a linear or a macrocyclic chelate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Many studies have shown that GdBCAs induce potent metabolic changes in cells, including increased hyaluronan and collagen production by fibroblasts, increased production of proinflammatory cytokines by peripheral blood mononuclear cells (PBMCs) and macrophages, as well as increased differentiation of PBMCs into fibrocytes. Previous studies have also shown that Omniscan upregulates several innate immunity pathways in normal differentiated human macrophages.

While it has long been known that patients with renal insufficiency are vulnerable to GdBCA-induced NSF, the mechanism behind the pathogenesis has not been understood. A new study, published in the Journal of Immunology, provides the first thorough analysis of GdBCA stimulation of the innate immune system.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

According to corresponding author Sergio A. Jimenez, MD, codirector of the Jefferson Institute of Molecular Medicine at Thomas Jefferson University in Philadelphia, the results underscore “the idea that exogenous agents can trigger a fibrotic reaction that looks like scleroderma.” He explains that there have been several documented cases where an environmental contaminant triggered a fibrotic process. In the case of eosinophilia myalgia syndrome in the United States and toxic oil syndrome in Spain, the mechanism behind the progressive fibrosis was never understood.

TLRs have recently been proposed to play a role in innate immunity as well as the development of various fibrotic disorders such as systemic sclerosis and pulmonary fibrosis. Researchers have now discovered that both Omniscan and gadodiamide induce normal human differentiated macrophages to produce multiple profibrotic and proinflammatory cytokines, chemokines, and growth factors via signaling through both TLR4 and TLR7. The effect of Gd compounds on fibroblasts may also be due to signaling via TLR4 since fibroblasts also express TLR4 at on the cell surface.

The authors had previously shown that exposure of normal differentiated human macrophages to Omniscan upregulated IFN-responsive genes as well as activated NF-ĸB. They began their current study by investigating the ability of GdBCAs to induce NF-ĸB activation of human embryonic kidney (HEK)293 cells expressing multiple human TLRs and two human NOD-like receptors (NLRs).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Research Reviews, Scleroderma Tagged With: Nephrogenic Systemic Fibrosis, Systemic sclerosis, Toll-like receptors

You Might Also Like:
  • Research Links Macrophages with Pathogenesis of Inflammation, Fibrosis
  • Rheuminations: Rheumatologists Seek Better Understanding of Fibrosing Disorders
  • FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment
  • Insights into Celiac Disease & Systemic Autoimmune Diseases

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)